# ClinicalTrials.gov record NCT01562678

> PeptideScanner retained ClinicalTrials.gov record NCT01562678 at 2026-07-30T21:24:24.231Z. Its registry update date was 2017-05-31, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01562678-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-05-31
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01562678-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct01562678-liraglutide-v1.json
- Content SHA-256: `a185c84452b3246ad8747aa6e22443abdc4b3b9cd0c72a0e72a6420e39bd773d`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT01562678 ([`ctg-observation-nct01562678-2017-05-31-efb992e7bc01`](#source-ctg-observation-nct01562678-2017-05-31-efb992e7bc01))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01562678 at 2026-07-30T21:24:24.231Z. Its registry update date was 2017-05-31, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01562678-2017-05-31-efb992e7bc01`](#source-ctg-observation-nct01562678-2017-05-31-efb992e7bc01))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01562678 at 2026-07-30T21:24:24.231Z. Its registry update date was 2017-05-31, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01562678-2017-05-31-efb992e7bc01`](#source-ctg-observation-nct01562678-2017-05-31-efb992e7bc01))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01562678-2017-05-31-efb992e7bc01`](#source-ctg-observation-nct01562678-2017-05-31-efb992e7bc01))

## Sources

<a id="source-ctg-observation-nct01562678-2017-05-31-efb992e7bc01"></a>
- **ClinicalTrials.gov record NCT01562678 · retained source version 2017-05-31:efb992e7bc017434de2693218744adccc275ddc2fc4b46456849c25581ebc697** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01562678) (`ctg-observation-nct01562678-2017-05-31-efb992e7bc01`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01562678." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct01562678-liraglutide-v1.json SHA-256: a185c84452b3246ad8747aa6e22443abdc4b3b9cd0c72a0e72a6420e39bd773d.